<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897490</url>
  </required_header>
  <id_info>
    <org_study_id>GATLA 11-LPA-20</org_study_id>
    <nct_id>NCT04897490</nct_id>
  </id_info>
  <brief_title>RWE of 1st Line Treatment With ATO/ATRA for Adult APL</brief_title>
  <official_title>Real World Evidence of First Line Treatment With Arsenic Trioxide Plus All Trans Retinoic Acid in Adult Patients With Acute Promyelocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Argentino de Tratamiento de la Leucemia Aguda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Argentino de Tratamiento de la Leucemia Aguda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational real world clinical trial with prospective follow up&#xD;
      that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in&#xD;
      the first line with arsenic trioxide and all trans retinoic acid (ATO/ATRA) based regimenes&#xD;
      in Argentina.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to gather real world evidence of the characteristics of APL&#xD;
      patients in Argentina who receive ATO/ATRA based treatment in first line following our&#xD;
      national guidelines. The study primary endpoint is to evaluate event free survival and&#xD;
      overall survival of patients diagnosed with APL and treated in first line with ATO/ATRA or&#xD;
      ATO/ATRA/Idarubicin (IDA) depending on risk category. Secondary endpoints are complete&#xD;
      molecular response (CMR) rate, toxicity, early mortality and prognostic significance of FLT3.&#xD;
&#xD;
      Every APL patient diagnosed in our institutions will follow our guidelines with respect to&#xD;
      diagnosis procedures. Risk category will depend on white blood cell counts (WBC), where WBC&#xD;
      &gt;10000 will be considered high risk (HR) and &lt;10000 WBC, low risk (LR).&#xD;
&#xD;
      Patients will receive induction with ATO plus ATRA daily until hematologic remission or for a&#xD;
      maximum of 60 days, followed by ATO 5 days/week, 4 weeks on 4 weeks off, for a total of 4&#xD;
      courses and ATRA 2 weeks on and 2 weeks off for a total of 7 courses.&#xD;
&#xD;
      HR patients will receive 2-3 doses of IDA at the beginning of induction. Central nervous&#xD;
      system prophylaxis is contemplated for HR pts or those who have SNC bleeding.&#xD;
&#xD;
      Molecular response will be evaluated at the end of consolidation by RQ-PCR. LR patients who&#xD;
      achieve CMR will not need to repeat molecular evaluations but HR patients will need RQ-PCR&#xD;
      evaluation every 3 months during the first year and every 6 months during the second year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate overall survival of patients diagnosed with APL and treated in first line with ATO/ATRA or ATO/ATRA/Idarubicin (IDA).</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate overall survival of patients &gt;/= 18 years old diagnosed with APL and treated in first line with ATO/ATRA or ATO/ATRA/Idarubicin (IDA) depending on risk category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate event free survival of patients diagnosed with APL and treated in first line with ATO/ATRA or ATO/ATRA/Idarubicin (IDA).</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate event free survival of patients &gt;/= 18 years old diagnosed with APL and treated in first line with ATO/ATRA or ATO/ATRA/Idarubicin (IDA) depending on risk category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate complete molecular remission rate at the end of the consolidation treatment.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate toxicity of the ATO/ATRA scheme (+/- IDA), measured according to type, frequency, severity and relation with the treatment of adverse events.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record early mortality (within 30 days of admission).</measure>
    <time_frame>Within 30 days of admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate whether the presence of mutated FLT3 has prognostic value in patients treated with ATRA/ATO.</measure>
    <time_frame>36 months</time_frame>
    <description>The prognostic value will be analyzed by comparing rates of complete remission (CR), hematological relapse, molecular relapse, PFS and OS.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Promyelocytic Leukemia, Adult Acute</condition>
  <arm_group>
    <arm_group_label>Adult APL in first line</arm_group_label>
    <description>Patients &gt;/= 18 years old with recent diagnosis of acute promyelocytic leukemia who receive treatment with ATO/ATRA according to our local guidelines. HR patients will receive 2-3 aditional doses of idarrubicin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of first line treatment with ATO/ATRA outcome</intervention_name>
    <description>Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.</description>
    <arm_group_label>Adult APL in first line</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with APL in first line treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years or older.&#xD;
&#xD;
          -  Signature of the form consent for participation in the study.&#xD;
&#xD;
          -  Diagnosis of APL (either primary or secondary) according to the criteria of the World&#xD;
             Health Organization (WHO), without prior treatment.&#xD;
&#xD;
          -  Identification of the specific genetic alteration of APL by conventional karyotype,&#xD;
             fluorescent in situ hybridization (FISH), reverse transcriptase polymerase chain&#xD;
             reaction (RT-PCR or RQ-PCR). Identification of the transcript is recommended at the&#xD;
             time of diagnosis isoforms: bcr1, bcr2, bcr3 essential to document the therapeutic&#xD;
             response: Molecular remission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other concomitant active malignant tumors that require simultaneous&#xD;
             treatment.&#xD;
&#xD;
          -  Having received prior treatment for APL.&#xD;
&#xD;
          -  Electrocardiogram abnormalities:&#xD;
&#xD;
               1. Patients with a pre-existing diagnosis of Long QT Syndrome&#xD;
&#xD;
               2. Patients with a baseline QTc of&gt; 450msec. The Bazett formula should be used to&#xD;
                  measure the corrected QT interval (QT interval in msec divided by the square root&#xD;
                  of the RR interval in msec).&#xD;
&#xD;
               3. Patients with a history or presence of significant ventricular or atrial&#xD;
                  tachyarrhythmia (Grade 3-4, CTCAE v5.2017).&#xD;
&#xD;
               4. Patients with right bundle branch block plus left anterior hemiblock.&#xD;
                  Bifascicular blocks are excluded.&#xD;
&#xD;
          -  ECOG score 4.&#xD;
&#xD;
          -  Stage III-IV heart failure.&#xD;
&#xD;
          -  Serum creatinine ≥ 2.5 mg / dL (≥ 250 μmol / L) unless due to APL.&#xD;
&#xD;
          -  Bilirubin ≥ 2.5 mg / dL, alkaline phosphatase, GPT or GOT&gt; 3 times the normal limit&#xD;
             unless it is for APL.&#xD;
&#xD;
          -  Severe psychiatric illness.&#xD;
&#xD;
          -  Women who are pregnant or who have decided to continue breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María José Mela Osorio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Argentino de Tratamiento de la Leucemia Aguda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isolda Fernández</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Argentino de Tratamiento de la Leucemia Aguda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Sackmann</last_name>
    <phone>5491149720765</phone>
    <email>fsackmann@fundaleu.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Freigeiro</last_name>
    <email>gatla.ar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CEMIC</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Cazap</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FUNDALEU</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Sackmann</last_name>
      <phone>541148771000</phone>
      <email>fsackmann@fundaleu.org.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Promyelocytic Leukemia</keyword>
  <keyword>ATRA</keyword>
  <keyword>ATO</keyword>
  <keyword>IDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Share study protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data will become available on June 2021, and will remain available until the end of the clinical trial.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

